Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-07-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0903PMID 27390348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

  2017cited by this paper
• Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

  2016cited by this paper
• Biomarkers associated with checkpoint inhibitors.

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016influential reference
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Microsatellite Instability as a Biomarker for PD-1 Blockade

  2016cited by this paper
• Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

  2016cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015influential reference
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer.

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• The Molecular Taxonomy of Primary Prostate Cancer.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

  2015cited by this paper
• Immunoinformatics and epitope prediction in the age of genomic medicine

  2015cited by this paper
• Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015influential reference
• Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

  2015cited by this paper
• PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

  2015cited by this paper
• Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

  2015cited by this paper
• Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015influential reference
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• Automated benchmarking of peptide-MHC class I binding predictions

  2015cited by this paper
• Microsatellite instability in gallbladder carcinoma

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014influential reference
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

  2014cited by this paper
• Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Familial pancreatic cancer: genetic advances

  2014cited by this paper
• Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

  2014cited by this paper
• Mechanisms underlying mutational signatures in human cancers

  2014cited by this paper
• Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

  2014cited by this paper
• Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

  2014cited by this paper
• Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma

  2014cited by this paper
• Promoter Methylation of MLH1, PMS2, MSH2 and p16 Is a Phenomenon of Advanced-Stage HCCs

  2014cited by this paper
• OptiType: precision HLA typing from next-generation sequencing data

  2014cited by this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cited by this paper
• Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

  2014cited by this paper
• Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• The causes and consequences of genetic heterogeneity in cancer evolution

  2013cited by this paper
• Mutation Inactivation of Nijmegen Breakage Syndrome Gene (NBS1) in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

  2013cited by this paper
• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

  2013cited by this paper
• COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA

  2013cited by this paper
• Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.

  2013cited by this paper
• B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells

  2013cited by this paper
• Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma.

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012influential reference
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• The cancer antigenome

  2012cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

  2012cited by this paper
• The DNA damage response and cancer therapy

  2012cited by this paper
• The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Interferon-inducible effector mechanisms in cell-autonomous immunity

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010influential reference
• Regulation of DNA polymerase POLD4 influences genomic instability in lung cancer.

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

  2010cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Mismatch repair deficient colorectal cancer in the era of personalized treatment

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.

  2009cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009influential reference
• Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

  2009cited by this paper
• NetMHCpan, a method for MHC class I binding prediction beyond humans

  2008cited by this paper
• Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers

  2008cited by this paper
• Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability

  2007cited by this paper
• PREDTAP: a system for prediction of peptide binding to the human transporter associated with antigen processing

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications

  2005cited by this paper
• The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

  2005cited by this paper
• Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

  2005cited by this paper
• Mutations induced by ultraviolet light.

  2005cited by this paper

• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026cites this paper
• Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in lung adenocarcinoma

  2026cites this paper
• Automated quantification of tumor-infiltrating lymphocytes by machine learning reveals prognostic and immunogenomic features in lung cancer

  2026cites this paper
• PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma.

  2026cites this paper
• Prognostic and Predictive Value of Machine Learning‐Based Biomarker and Pathomics Signatures in Patients With Prostate Cancer

  2025cites this paper
• ADME gene-driven prognostic model for bladder cancer: a breakthrough in predicting survival and personalized treatment

  2025cites this paper
• Identify Modules Associated with Immunotherapy Response from Mouse Tumor Profiles for Stratifying Cancer Patients

  2025cites this paper
• The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild‐Type Non‐Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells

  2025cites this paper
• Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss

  2025cites this paper
• Integrating machine learning models with multi-omics analysis to decipher the prognostic significance of mitotic catastrophe heterogeneity in bladder cancer

  2025cites this paper
• Development and validation of a gene signature for gastric cancer prognosis based on propionate metabolism

  2025cites this paper
• Predictive value of NUF2 for prognosis and immunotherapy responses in pan-cancer.

  2025cites this paper
• Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration

  2025cites this paper
• Comprehensive analysis of single-cell and bulk RNA sequencing data unveils antigen-presenting and processing fibroblasts and establishes a predictive model in gastric cancer

  2025cites this paper
• PD-L1 Expression in NSCLC: Clouds in a Bright Sky

  2025cites this paper
• Identification of novel gene-based risk score for prognosis in prostate cancer

  2025cites this paper
• Advances in the relationship of immune checkpoint inhibitors and DNA damage repair.

  2025cites this paper
• Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab

  2025cites this paper
• Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma

  2025cites this paper
• NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target

  2024cites this paper
• Therapeutic Vaccination Strategies for Breast Cancer

  2024cites this paper
• Clinical implications of PD-L1 expression and pathway-related molecular subtypes in advanced Asian colorectal cancer patients.

  2024cites this paper
• Advances in molecular basis of response to immunotherapy for penile cancer: better screening of responders

  2024cites this paper
• Prospects and challenges of neoantigen applications in oncology.

  2024cites this paper
• Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

  2024cites this paper
• Developing a machine learning-based prognosis and immunotherapeutic response signature in colorectal cancer: insights from ferroptosis, fatty acid dynamics, and the tumor microenvironment

  2024cites this paper
• The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade

  2024cites this paper
• Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors

  2024cites this paper
• Advances in Prostate Cancer Immunotherapy: Current Options and Emerging Novel Approaches

  2024cites this paper
• Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer

  2024cites this paper
• Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study

  2024cites this paper
• Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

  2024cites this paper
• Comprehensive bioinformatics analysis of human cytomegalovirus pathway genes in pan-cancer

  2024cites this paper
• Predictive Biomarkers in PD-1/PD-L1 Immunotherapy Response: A Machine Learning Approach Using Gene Sequencing Data

  2024cites this paper
• Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies

  2024cites this paper
• Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations.

  2024cites this paper
• A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer

  2024cites this paper
• GJB3: a comprehensive biomarker in pan-cancer prognosis and immunotherapy prediction

  2024cites this paper
• Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design

  2024cites this paper
• Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer

  2024cites this paper
• Cuproptosis facilitates immune activation but promotes immune escape, and a machine learning–based cuproptosis‐related signature is identified for predicting prognosis and immunotherapy response of gliomas

  2023cites this paper
• Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors

  2023cites this paper
• Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3

  2023cites this paper
• Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy

  2023cites this paper
• The Future of Precision Oncology

  2023cites this paper
• Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-γ/JAK/STAT-1

  2023cites this paper
• Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy

  2023influential citation
• Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro.

  2023cites this paper
• Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade

  2023cites this paper
• Clinical efficacy of PARP inhibitors in breast cancer

  2023cites this paper
• A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

  2023cites this paper
• Cuproptosis‐related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features

  2023cites this paper
• Bcl-xL mediates interferon-beta secretion by protease-activated receptor 2 deficiency through the mitochondrial permeability transition pore in colorectal cancer metastasis.

  2023cites this paper
• The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

  2023cites this paper
• Anoikis-related long non-coding RNA signatures to predict prognosis and small molecular drug response in cervical cancer

  2023cites this paper
• Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

  2023cites this paper
• Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer

  2022cites this paper
• Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients

  2022cites this paper
• CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma

  2022cites this paper
• Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis

  2022cites this paper
• A Review On: Role of Exosomes in Cancer Therapy

  2022cites this paper
• Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors

  2022cites this paper
• Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

  2022cites this paper
• Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.

  2022cites this paper
• Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein–Barr Virus Infection

  2022cites this paper
• Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma

  2022cites this paper
• A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy

  2022cites this paper
• Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response

  2022cites this paper
• A novel prognostic signature based on N7-methylguanosine-related long non-coding RNAs in breast cancer

  2022cites this paper
• Theranostic Radiolabeled Nanomaterials for Molecular Imaging and potential Immunomodulation Effects

  2022cites this paper
• Harnessing chitosan and poly-(γ-glutamic acid)-based biomaterials towards cancer immunotherapy

  2022cites this paper
• Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma.

  2022cites this paper
• Identifying tumor antigens and immuno‐subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine

  2022cites this paper
• Exosomes as Drug Carriers in Anti-Cancer Therapy

  2022cites this paper
• Deoxyribonucleic Acid Damage Response Defects

  2022cites this paper
• Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade.

  2022cites this paper
• Melanoma: An immunotherapy journey from bench to bedside.

  2022cites this paper
• Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

  2021cites this paper
• Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients

  2021cites this paper
• Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

  2021cites this paper
• Rare cases of medulloblastoma with hypermutation

  2021cites this paper
• Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses

  2021cites this paper
• TMB or not TMB as a biomarker: That is the question.

  2021cites this paper
• A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma

  2021cites this paper
• Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies.

  2021cites this paper
• PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

  2021cites this paper
• PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

  2021cites this paper
• Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients

  2021cites this paper
• A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma

  2021cites this paper
• Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.

  2021cites this paper
• The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

  2021cites this paper
• Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer

  2021cites this paper
• 肿瘤突变负荷应用于肺癌免疫治疗的专家共识

  2021cites this paper
• Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer

  2021cites this paper
• Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

  2021cites this paper
• Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer

  2021cites this paper
• Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review

  2021cites this paper
• Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing

  2021cites this paper
• Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy

  2021cites this paper
• A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma

  2021cites this paper